SUMMIT (OXFORD) LIMITED

• ⚠

  Confirmation statement overdue

  Due 2026-01-25.

• ⚠

  Material uncertainty over going concern

  Until additional funding is secured, these circumstances cast significant doubt upon the ability of the Group to continue to support the Company to meet its liabilities as they fall due, which in turn indicates the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

1. SUMMIT (OXFORD) LIMITED 2007-08-06 → present
2. VASTOX CHEMICAL GENOMICS LIMITED 2004-09-30 → 2007-08-06
3. VASTOX LIMITED 2003-01-14 → 2004-09-30

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“Until additional funding is secured, these circumstances cast significant doubt upon the ability of the Group to continue to support the Company to meet its liabilities as they fall due, which in turn indicates the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.”

Significant events

• “On April 29, 2025, the Compensation Committee and the Board of Summit Therapeutics Inc (the Company's ultimate parent) approved a modification to the Company's outstanding unvested performance-based stock option awards issued under the Company's 2020 Stock Incentive Plan for employees, that will require only the service-based vesting requirements to continue to be satisfied in order to become fully vested, subject to employee consent. Approximately 277,400 of the Company's outstanding unvested performance-based stock option awards were modified to service-based options awards that vest annually over 4 years beginning on January 1, 2025. The impact of this modification will be recorded in the Company's financial statements beginning with the year ending December 31, 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  +35.7%

  £798,973 → £1,084,055

• Net assets

  +19.8%

  -£8,017,599 → -£6,432,909

• Employees

  -8.3%

  12 → 11

• Operating profit

  +60.2%

  -£3,255,071 → -£1,296,947

• Profit before tax

  +59.7%

  -£3,295,078 → -£1,326,808

• Wages

  -15.9%

  £1,815,021 → £1,525,920

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers